Compare Abbott Laboratories (ABT) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs KeyCorp — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while KeyCorp trades at $22.63 (market cap $25.22B). The key difference: Abbott Laboratories is far larger — about 6.6× KeyCorp's market cap, and KeyCorp pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| ABT | KEY | |
|---|---|---|
Market Cap | $166.94B | $25.22B |
Sector | Health | Financials |
52-Week High | $136.62 | $23.43 |
52-Week Low | $82.57 | $16.78 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
KeyCorp (KEY) trades at $23.37, up 1.52% today, with a bullish technical signal and strong earnings momentum after three consecutive quarterly beats. The stock shows robust fundamentals with a P/E of 14.37, net income margin of 26.05%, and a new $3 billion buyback program. Recent news highlights its inclusion in dividend-focused strategies and potential for further earnings outperformance.
Outlook remains positive given analyst consensus of $29.55 price target and 60.79% buy ratings. Risks include volatile cash flows and banking sector sensitivity to interest rates, but capital returns and earnings growth support upside potential for investors seeking value and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
